Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Inclusion Criteria:

- Diagnosis of advanced malignancy, Non-Small Cell Lung Cancer (NSCLC) only during
stage 1 of accrual

- Non-synonymous mutation of B-RAF or DDR2, defined as follows:

- NSCLC with inactivating B-RAF mutation

- NSCLC of squamous type with DDR2 mutation

- Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation,
or NSCLC or melanoma having a B-RAF mutation which is not functionally
characterized

- At least one target lesion per Response Evaluation Criteria in Solid Tumors (RECIST)
1.1 criteria on baseline staging evaluation

- Disease progression after ≥ 1 prior treatment regimen *Exception: Subjects with NSCLC
of squamous type may be enrolled in first line, no prior treatment is required

Exclusion Criteria:

- Pleural or pericardial effusion Grade > 1

- QTcF > 470 msec (Grade ≥ 2) or diagnosed congenital long QT syndrome

- Absolute granulocyte count < 1,500/mm3

- Hemoglobin < 10 g/dL

- Platelet count < 75,000/mm3

- Serum calcium < institutional Lower limit of normal (LLN)

- Hypokalemia, hypophosphatemia or hypomagnesemia Grade > 1, despite supplementation

- Creatinine > 3 x institutional Upper Limit of Normal (ULN)

- Total bilirubin > 1.5 x ULN

- Alanine transaminase (ALT) > 3 x ULN